NCT02624154

Brief Summary

Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2015

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2015

Completed
1 day until next milestone

Study Start

First participant enrolled

December 1, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 8, 2015

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

December 8, 2015

Status Verified

November 1, 2015

Enrollment Period

6 months

First QC Date

November 30, 2015

Last Update Submit

December 4, 2015

Conditions

Pancreatic Neuroendocrine Tumor

Outcome Measures

Primary Outcomes (1)

  • The survival rate

    3 years

Interventions

pancreatectomyPROCEDURE

Remove the pancreatic neuroendocrine tumor by surgery

Eligibility Criteria

Age10 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Investigators selected the patient who underwent pancreatectomy during the time from 2010 to 2013 at the First Affiliated Hospital of Sun Yat-sen University.

You may qualify if:

  • The patients with pancreatic neuroendocrine tumor underwent pancreatectomy

You may not qualify if:

  • The patients with pancreatic neuroendocrine tumor did not undergo pancreatectomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Adenoma, Islet Cell

Interventions

Pancreatectomy

Condition Hierarchy (Ancestors)

AdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsPancreatic NeoplasmsDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Digestive System Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Shaowei Gao, Doctor

    First Affiliated Hospital, Sun Yat-Sen University

    STUDY DIRECTOR

Central Study Contacts

Qinchang Chen, Doctor

CONTACT

18819430530337809622@qq.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 30, 2015

First Posted

December 8, 2015

Study Start

December 1, 2015

Primary Completion

June 1, 2016

Study Completion

December 1, 2016

Last Updated

December 8, 2015

Record last verified: 2015-11